{"id":"fk199b","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FK199B blocks the C5a receptor on immune cells, preventing the recruitment and activation of neutrophils and other inflammatory cells downstream of complement cascade activation. This mechanism reduces tissue damage and inflammation in complement-driven diseases. It represents a targeted approach to modulating innate immunity without broad immunosuppression.","oneSentence":"FK199B is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:12:46.265Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complement-mediated inflammatory disorders (specific indication under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT00432198","phase":"PHASE4","title":"Zolpidem Postmarketing Study in Adolescent Patients With Insomnia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-02","conditions":"Insomnia","enrollment":122},{"nctId":"NCT00283946","phase":"PHASE3","title":"A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-02","conditions":"Sleep Initiation and Maintenance Disorders, Sleep Disorders","enrollment":876},{"nctId":"NCT00374777","phase":"PHASE3","title":"A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-08","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":450},{"nctId":"NCT00999219","phase":"PHASE3","title":"A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-03","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zolpidem MR Tablet"],"phase":"phase_3","status":"active","brandName":"FK199B","genericName":"FK199B","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FK199B is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation. Used for Complement-mediated inflammatory disorders (specific indication under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}